Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00241501 · ClinicalTrials.gov registry record · Phase 3
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00241501 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 140 participants.
The verdict
NCT00241501, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age, inclusive, with clinically diagnosed GERD. The treatment period will be up to 8 weeks.
Interventions
- DRUG Esomeprazole (Nexium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00241501
The ClinicalTrials.gov registry entry for NCT00241501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole (Nexium) is the first listed.
NCT00241501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00241501 about?
NCT00241501 is a clinical study titled "Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients". This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age, inclusive, with clinically diagnosed GERD. The treatment period will be up t...
What is the current status of trial NCT00241501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2004-02. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00241501?
The interventions under investigation include: Esomeprazole (Nexium) (DRUG).
Who is sponsoring clinical trial NCT00241501?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.